Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, will be represented at next month’s 2024 BIO International Convention; the convention is scheduled to take place June 3–6, 2024, in San Diego, California. According to the announcement, Longeveron officials will meet with executives from global pharmaceutical companies to discuss possible partnerships and other opportunities for LGVN’s Alzheimer’s disease program. The company has reported positive results obtained from its recent phase 1 and phase 2 (CLEAR MIND) clinical trials. The company noted that full results from the CLEAR MIND study were selected for an oral presentation at this year’s Alzheimer’s Association International Conference (AAIC). “Longeveron’s lead investigational therapeutic candidate is Lomecel-B(TM), a proprietary, scalable, allogenic cellular therapy,” said the company in the press release. “In a completed phase 2a clinical trial, Lomecel-B-treated patients showed an overall slowing/prevention of disease worsening compared to placebo. The trial achieved the primary safety and secondary efficacy endpoints and showed statistically significant improvements in prespecified clinical and biomarker endpoints in specific Lomecel-B groups compared to placebo. These results support the therapeutic potential of Lomecel-B in the treatment of mild Alzheimer’s disease and provided evidence-based support for further clinical development.”
To view the full press release, visit https://ibn.fm/rw2nK
About Longeveron Inc.
Longeveron is a clinical-stage, biotechnology company developing regenerative medicines to address unmet medical needs. The company’s lead investigational product is Lomecel-B(TM), an allogeneic medicinal signaling cell (“MSC”) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B(TM) has multiple potential mechanisms of action encompassing provascular, proregenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty. To learn more about the company, visit www.Longeveron.com.
NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at https://ibn.fm/LGVN
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
